L-902688 is an orally active EP4 receptor agonist (Ki: 0.38 nM; EC50: 0.6 nM). L-902688 displays >4,000-fold selective for EP4 over other EP and prostanoid receptors.

L-902688 (1 μM; 24 hours; HUVE cells) treatment, decreases TGF-β-induced Twist and α-smooth muscle actin (α-SMA) expression.

In the monocrotaline (MCT)-induced PAH rat model, L-902688 (0.25-1 μg/kg/day; intraperitoneal injection; daily; for 3 weeks; adult male Sprague-Dawley rats) treatment decreases right ventricle fibrosis [1].

634193-54-7

C21H27F2N5O2

419.47

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years